Rivista

The efficacy of CHOEP chemotherapyregimenadministered in association with monoclonalantibody anti-CD52 Alemtuzumab in cutaneous T-celllymphoma (CTCL) and systemic T-celllymphoma with cutaneousinvolvement (PTCL)

Autori: Postorino M, De Santis G, Marchesi F, Provenzano I, Franceschini L, Pupo L, Rizzo M, Giannì L, Gumenyuk S, Tonialini L, Fiorelli E, Renzi D, Zizzari A.

Data: 2013

Ambito di interesse: Ematologia

Rivista: (Abstract) 12th International Congress of MalignantLymphoma, Lugano 2013. HematolOncol 2013; 31 (Suppl. 1): 201–270

Potrebbero interessarti anche:

Rivista 2,4

Daclatasvir, sofosbuvir with or without ribavirin for 24 weeks in hepatitis C genotype 3 cirrhosis: A real-life study.

Autori: lionetti R

Data: May 2019

Ambito di interesse: infettivologico/epatologico

Rivista: Ann Hepat

Leggi dettagli

Rivista 11.8

Variable course of Unverricht-Lundborg disease: Early prognostic factors. – IF 11.8

Autori: Canafoglia L, Ferlazzo E, Michelucci R, Striano P, Magaudda A, Gambardella A, Pasini E, Belcastro V, Riguzzi P, Fanella M, Granata T, Beccaria F, Trentini C, Bianchi A, Aguglia U, Panzica F, Franceschetti S.

Data: 2017

Ambito di interesse: Epilessia

Rivista: Neurology. 2017 Sep 20

Leggi dettagli

Rivista 3,7

Comparison between alcohol- and hepatitis C virus-related hepatocellular carcinoma: clinical presentation, treatment and outcome.

Autori: Bucci L et al

Data: 16 feb 2023

Ambito di interesse: epatologico

Rivista: Liver Cancer

Leggi dettagli

The efficacy of CHOEP chemotherapyregimenadministered in association with monoclonalantibody anti-CD52 Alemtuzumab in cutaneous T-celllymphoma (CTCL) and systemic T-celllymphoma with cutaneousinvolvement (PTCL)

Potrebbero interessarti anche:

Daclatasvir, sofosbuvir with or without ribavirin for 24 weeks in hepatitis C genotype 3 cirrhosis: A real-life study.

Variable course of Unverricht-Lundborg disease: Early prognostic factors. – IF 11.8

Comparison between alcohol- and hepatitis C virus-related hepatocellular carcinoma: clinical presentation, treatment and outcome.

Cosa fare per